Efficacy and safety of dapsone as second line therapy for adult immune thrombocytopenia: A retrospective study of 42 patients

PloS One
Clémentine EstèveSylvain Audia

Abstract

Dapsone is recommended as a second line therapy in immune thrombocytopenia (ITP), but is underused because of its potential side effects. The medical charts of 42 ITP patients treated with dapsone (100 mg/day) were retrospectively reviewed in order to assess its efficacy and safety in daily clinical practice. The overall response rate was 54.8% (n = 22, with a complete response in 38.1%) with a median time to response of 29 days (24-41 days). Patients with complete response had shorter disease duration whereas no difference was observed between responders and non-responders regarding age, sex or previous treatments received. Importantly, after dapsone withdrawal, a sustained response was observed in 5 patients, representing 12% of the whole cohort. Twenty percent of patients (n = 8) relapsed on therapy after 8.1 (6.5-13.6) months. Side effects occurred in 31% (n = 13) of patients, and required dapsone withdrawal in 22% (n = 9) or dosage reduction in 10% (n = 4) of the cases. Side effects resolved in all but one case. Overall, these data support dapsone as an interesting second line therapy in ITP, with a good safety and efficacy profile at a low cost.

References

Jul 1, 1991·British Journal of Haematology·J M DurandJ Soubeyrand
Jul 23, 1988·BMJ : British Medical Journal·C Moss, P J Hamilton
Jun 1, 1995·British Journal of Haematology·F HernándezM Perella
Sep 1, 1993·American Journal of Hematology·B GodeauP Bierling
May 1, 1997·British Journal of Haematology·B GodeauP Bierling
Mar 29, 2002·The New England Journal of Medicine·Douglas B Cines, Victor S Blanchette
Feb 7, 2003·Journal of Pediatric Hematology/oncology·Nathan D MeekerWilliam B Slayton
Feb 18, 2003·British Journal of Haematology·UNKNOWN British Committee for Standards in Haematology General Haematology Task Force
Apr 20, 2004·The American Journal of Medicine·Frédéric MaloiselPatrick Dufour
Sep 9, 2005·European Journal of Haematology·Sharat DamodarAlok Srivastava
Jan 4, 2007·Annals of Internal Medicine·Donald M ArnoldJohn G Kelton
Nov 4, 2008·Platelets·Suley Mara Chaddad Vancine-CalifaniJoyce Maria Annichino-Bizzacchi
Apr 23, 2010·La Revue de médecine interne·S AudiaB Bonnotte
Feb 18, 2011·Blood·Cindy NeunertUNKNOWN American Society of Hematology
Aug 10, 2013·Journal of Thrombosis and Haemostasis : JTH·C Rodrigo, L Gooneratne
Feb 12, 2014·Platelets·Ashwin P Patel, Amit S Patil
Aug 31, 2014·La Revue de médecine interne·V LoustauB Godeau
Nov 18, 2014·American Journal of Hematology·Tomás José González-LópezJosé Ramón González-Porras
Oct 1, 2015·La Revue de médecine interne·S AudiaB Bonnotte

❮ Previous
Next ❯

Citations

Aug 21, 2019·Toxicological Sciences : an Official Journal of the Society of Toxicology·Yiying BianJin-Ho Chung
Dec 22, 2019·BMJ Case Reports·Preeti DalalAnita Tahlan
Mar 29, 2019·Current Opinion in Rheumatology·Ruba Kado, W Joseph McCune
Aug 4, 2020·La Revue de médecine interne·S AudiaB Bonnotte
May 22, 2021·Journal of Thrombosis and Haemostasis : JTH·Marina P ColellaJoyce M Annichino-Bizzacchi
Oct 11, 2021·The Medical Journal of Australia·Philip Yi ChoiRobert Bird

❮ Previous
Next ❯

Software Mentioned

ITP
STATA

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.